Past or current EBV exposure.
Epstein-Barr Virus and Infectious Mononucleosis
Epstein-Barr Virus (EBV), a widespread and persistent herpesvirus, is primarily known for causing Infectious Mononucleosis, often referred to as "Mono" or the "kissing disease." EBV, discovered in 1964, is remarkably prevalent, infecting over 90% of the global adult population. The virus is typically transmitted through bodily fluids, particularly saliva, which is why Mono has garnered its nickname. Once infected, individuals may experience a range of symptoms, including but not limited to fatigue, fever, inflamed throat, swollen lymph nodes, and an enlarged spleen. These symptoms usually manifest four to six weeks after exposure and can vary in intensity and duration. Interestingly, EBV can also remain dormant in the body and potentially reactivate later in life, though usually without symptoms. Moreover, the virus has been linked to certain types of cancers and autoimmune diseases, making its study crucial in medical research. Vaccines against EBV are currently under development, aiming to reduce the risks associated with the virus. Understanding the dynamics of Epstein-Barr Virus and Infectious Mononucleosis is essential, not only for medical professionals but also for individuals, to promote effective prevention and treatment strategies.
Biomarkers related to this condition
6 markers commonly used to screen, diagnose, or monitor Epstein-Barr Virus and Infectious Mononucleosis
Helps identify recent EBV infection; interpret with VCA IgG and EBNA.
Antibody to the Epstein-Barr virus capsid antigen, IgG class.
Epstein-Barr virus nuclear antigen antibody in serum
Epstein-Barr virus capsid antibody, IgG class, in blood.
White blood cells fighting infection